Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IONIS PHARMACEUTICALS INC Director's Dealing 2018

Jan 31, 2018

30591_dirs_2018-01-31_6407f227-946b-4b9e-91a9-589542bb9674.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2018-01-30

Reporting Person: KLEIN JOSEPH III (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-01-30 Common Stock M 3000 $35.53 Acquired 12939 Direct
2018-01-30 Common Stock S 3000 $52.86 Disposed 9939 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-01-30 Employee Stock Option (right to buy) $35.53 M 3000 Acquired 2024-06-30 Common Stock (3000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 100 Indirect

Footnotes

F1: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.75 to $53.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.